Trend Aggregation Conservative ETF
Limited financial coverage for TACE.
Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.
Price Chart
About the company
This fund aims to generate a total return for investors. To achieve this, it strategically allocates capital to various exchange-traded funds (ETFs). These underlying ETFs predominantly focus on an eclectic mix of holdings, including debt instruments, real estate investment trusts (REITs), master limited partnerships (MLPs), income-generating equity stocks (such as those in the utility sector), put options, U.
- IPO
- 2020
- HQ
- US
Get TickerSpark's AI analysis on TACE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- 52W High
- $25.83
- 52W Low
- $23.82
- 50D MA
- $25.67
- 200D MA
- $25.53
- Beta
- 0.00
- RSI (14)
- 44
- Avg Volume
- 11.09K
No earnings-call transcripts are available for TACE yet.
- Free Float
- 0.0%
- Shares Outstanding
- 625.67K
- Float Shares
- 0
Our TACE coverage
Recent articles, reports, and earnings notes.
No research on TACE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TACE report →IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial
businesswire.com · Jun 1
Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types
gurufocus.com · Jun 1
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
gurufocus.com · May 28
Trend Aggregation Conservative ETF (NYSEARCA:TACE) Shares Down 0.2% – Should You Sell?
defenseworld.net · Jan 14
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma
businesswire.com · Sep 14
ETF Odds & Ends: 2 Closures Announced
etf.com · Sep 13
ETF Odds & Ends: Veterans Fund Closes
etf.com · Jul 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.